Vanda Pharmaceuticals Inc. (VNDA:NASDAQ) closed at $3.94 on October 26, 2026, down 1.75% on the day. The stock trades 60.4% below its 52-week high of $9.94 and 1.5% above its 52-week low of $3.88. Over the past year, it lost 29.8%. Vanda Pharmaceuticals Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 24, 2025, VNDA closed higher on 121 days (48%). Its best day was February 23, 2026 (+41.49%) and its worst was October 30, 2025 (-20.15%). The stock moved 10% or more in a single session 12 times. It opened at least 5% above the previous day's high 3 times.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. The company markets its products in the United States, Canada, Europe Union, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Find more stocks like VNDA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.